Digestive Tract Reconstruction After Gastrectomy of Gastric Cancer With Type 2 Diabetes
NCT ID: NCT01637350
Last Updated: 2016-02-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
60 participants
OBSERVATIONAL
2012-08-31
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Four Reconstructions After Total Gastrectomy
NCT00677456
Impact of Glycemic Variability on People With Gastrointestinal Cancer and Diabetes After Surgery
NCT07180251
Functional Jejunal Interposition Improve Nutritional Status After Total Gastrectomy
NCT01996059
Immunonutritional Supplement After Total Gastrectomy in Patients With Stage III Gastric Cancer
NCT05253716
ONS in Gastric Cancer After Total Gastrectomy
NCT05823272
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigators will observed fasting blood glucose, postprandial blood glucose, glycosylated hemoglobin, C -peptide and body weight of the patients preoperation, 14 days postoperation 3 month and 6month postoperation. The investigators will observed the effect of blood glucose to different digestive tract reconstruction after gastrectomy of gastric cancer with type 2 diabetes
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Subtotal gastrectomy , BillrothⅠ
digestive tract reconstruction
Subtotal gastrectomy with BillrothⅠ or BillrothⅡ, total gastrectomy with jejunal interposition or Roux-en-Y reconstruction
Subtotal gastrectomy , BillrothⅡ
digestive tract reconstruction
Subtotal gastrectomy with BillrothⅠ or BillrothⅡ, total gastrectomy with jejunal interposition or Roux-en-Y reconstruction
total gastrectomy, jejunal interposition
digestive tract reconstruction
Subtotal gastrectomy with BillrothⅠ or BillrothⅡ, total gastrectomy with jejunal interposition or Roux-en-Y reconstruction
total gastrectomy , Roux-en-Y
digestive tract reconstruction
Subtotal gastrectomy with BillrothⅠ or BillrothⅡ, total gastrectomy with jejunal interposition or Roux-en-Y reconstruction
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
digestive tract reconstruction
Subtotal gastrectomy with BillrothⅠ or BillrothⅡ, total gastrectomy with jejunal interposition or Roux-en-Y reconstruction
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. with type 2 diabetes,fasting blood glucose \> 6.1mmol/L
3. without serious underlying diseases which may affect the metabolism and nutrient uptake
4. without serious underlying diseases which may affect anesthesia and operation
5. can be performed subtotal or total gastrectomy, predicted survival period \> 6months
6. no other abdominal operation
7. preoperation consultation
8. informed consent
Exclusion Criteria
2. patient requests for quit
3. pregnancy
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tianjin Medical University Cancer Institute and Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhao Yan, Doctor
Role: STUDY_DIRECTOR
Tianjin Medical University Cancer Institute and Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CIH-WXN-201205001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.